[1]
|
Luke, T., et al. (2010) Hark back: passive immunotherapy for influenza and other serious infections. Critical Care Medicine, 38, e66-73.
doi:10.1097/CCM.0b013e3181d44c1e
|
[2]
|
Hoi, K.W., et al. (2010) Practical limitations of convalescent plasma collection: A case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion, 50, 1967-1971. doi:10.1111/j.1537-2995.2010.02651.x
|
[3]
|
Kreil, T.R., et al. (2012) Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: The example of pandemic H1N1 influenza. Transfusion, 52, 803-809.
doi:10.1111/j.1537-2995.2011.03347.x
|
[4]
|
Parry, R.P., et al. (2012) Strategies for screening blood donors to source convalescent H1N1v plasma for intervention therapy. Vox Sanguinis, 103, 107-112.
doi:10.1111/j.1423-0410.2012.01599.x
|
[5]
|
Wu, J.T., et al. (2010) Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic. Proceedings of the National Academy of Sciences, 107, 3269-3274.
doi:10.1073/pnas.0911596107
|
[6]
|
Leider, J.P., et al. (2010) Convalescent transfusion for pandemic influenza: Preparing blood banks for a new plasma product? Transfusion, 50, 1384-1398.
doi:10.1111/j.1537-2995.2010.02590.x
|
[7]
|
Kong, L. and Zhou, B. (2006) Successful treatment of avian influenza with convalescent plasma. Hong Kong Medical Journal, 12, 489.
|
[8]
|
Zhou, B., et al. (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. New England Journal of Medicine, 357, 1450-1451.
doi:10.1056/NEJMc070359
|
[9]
|
Hung, I.F., et al. (2011) Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinical Infectious Diseases, 52, 447-456. doi:10.1093/cid/ciq106
|
[10]
|
Gordon, C.L., et al. (2010) Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G2 subclass deficiency. Clinical Infectious Diseases, 50, 672-678. doi:10.1086/650462
|
[11]
|
Wang, H., et al. (2008) Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. The Lancet, 371, 1427-1434.
doi:10.1016/S0140-6736(08)60493-6
|
[12]
|
Yu, H., et al. (2008) Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in china. PLoS ONE, 3, e2985.
doi:10.1371/journal.pone.0002985
|
[13]
|
Boon, A.C.M., et al. (2010) Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model. Journal of Virology, 84, 7662-7667.
doi:10.1128/JVI.02444-09
|
[14]
|
Corti, D., et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science, 333, 850-856.
doi:10.1126/science.1205669
|
[15]
|
Hessel, A., et al. (2010) A pandemic influenza H1N1 live vaccine based on modified vaccinia ankara is highly immunogenic and protects mice in active and passive immunizations. PLoS ONE, 5, e12217.
doi:10.1371/journal.pone.0012217
|
[16]
|
Howard, M.K., et al. (2011) H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS ONE, 6, e23791. doi:10.1371/journal.pone.0012217
|
[17]
|
Kistner, O., et al. (2010) A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS ONE, 5, e9349.
doi:10.1371/journal.pone.0009349
|
[18]
|
Nguyen, H.H., et al. (2010) prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice. PLoS ONE, 5, e10152.
doi:10.1371/journal.pone.0010152
|
[19]
|
Shahzad, M., et al. (2008) Passive immunization against highly patho-genic Avian Influenza Virus (AIV) strain H7N3 with antiserum generated from viral polypeptides protect poultry birds from lethal viral infection. Virology Journal, 5, 144. doi:10.1186/1743-422X-5-144
|
[20]
|
Ekiert, D.C., et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science, 324, 246-251. doi:10.1126/science.1171491
|
[21]
|
Friesen, R.H.E., et al. (2010) New class of monoclonal antibodies against severe influenza: Prophylactic and therapeutic efficacy in ferrets. PLoS ONE, 5, e9106.
doi:10.1371/journal.pone.0009106
|
[22]
|
Oh, H.L.J., et al. (2010) An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 Influenza Viruses. Journal of Virology, 84, 8275-8286. doi:10.1128/JVI.02593-09
|
[23]
|
Ward, P., et al. (2005) Oseltamivir (Tamiflu?) and its potential for use in the event of an influenza pandemic. Journal of Antimicrobial Chemotherapy, 55, 5-21.
doi:10.1093/jac/dki018
|
[24]
|
Gubareva, L.V., et al. (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. Journal of Infectious Diseases, 183, 523-531. doi:10.1086/318537
|
[25]
|
Kiso, M., et al. (2004) Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. The Lancet, 364, 759-765.
doi:10.1016/S0140-6736(04)16934-1
|
[26]
|
Stephenson, I., et al. (2009) Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clinical Infectious Diseases, 48, 389-396. doi:10.1086/596311
|
[27]
|
Whitley, R., et al. (2001) Oral oseltamivir treatment of influenza in children. The Pediatric Infectious Disease Journal, 20, 127-133.
doi:10.1097/00006454-200102000-00002
|
[28]
|
Roche (2001) Clinical trial result information (JV16284). http://www.rochetrials.com/studyResultGet.action?studyResultNumber=JV16284&productName=Tamiflu& gener ic Name=Oseltamivir
|
[29]
|
Tramontana, A.R., et al. (2010) Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerging Infectious Diseases, 16, 1068-1075.
doi:10.3201/eid1607.091691
|
[30]
|
Carr, S., et al. (2011) Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. The Pediatric Infectious Disease Journal, 30, 284-288.
doi:10.1097/INF.0b013e3181ff863b
|
[31]
|
Srivastava, B., et al. (2009) Host genetic background strongly influences the response to influenza A virus infections. PLoS ONE, 4, e4857.
doi:10.1371/journal.pone.0004857
|
[32]
|
van der Laan, J.W., et al. (2008) Animal models in influenza vaccine testing. Expert Review of Vaccines, 7, 783-793. doi:10.1586/14760584.7.6.783
|
[33]
|
Barnard, D.L. (2009) Animal models for the study of influenza pathogenesis and therapy. Antiviral Research, 82, A110-A122. doi:10.1016/j.antiviral.2008.12.014
|
[34]
|
Sidwell, R.W., et al. (1998) Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Research, 37, 107-120. doi:10.1016/S0166-3542(97)00065-X
|
[35]
|
Mendel, D.B., et al. (1998) Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother, 42, 640-646.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC105511/pdf/ac000640.pdf
|
[36]
|
Yen, H.L., et al. (2005) Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. Journal of Infectious Diseases, 192, 665-672.
doi:10.1086/432008
|
[37]
|
Sidwell, R.W., et al. (2007) Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother, 51, 845-851. doi:10.1128/AAC.01051-06
|
[38]
|
Suguitan, A.L., et al. (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLOS Medicine, 3, e360.
doi:10.1371/journal.pmed.0030360
|
[39]
|
Tamura, S.I. (2010) Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine, 28, 6393-6397. doi:10.1016/j.vaccine.2010.05.019
|
[40]
|
Min, J.Y., et al. (2010) Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets. Virology, 408, 128-133.
doi:10.1016/j.virol.2010.09.009
|
[41]
|
Ison, M.G., et al. (2006) Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. Journal of Infectious Diseases, 193, 765-772.
doi:10.1086/500464
|
[42]
|
Reed, L. and Muench, H. (1938) A simple method of estimating fifty percent endpoints. The American Journal of Hygiene, 27, 493-497.
http://aje.oxfordjournals.org/content/27/3/493.short
|
[43]
|
Luke, T.C., et al. (2006) Meta-analysis: Convalescent blood products for spanish influenza pneumonia: A future H5N1 treatment? Annals of Internal Medicine, 145, 599.
http://annals.org/article.aspx?articleid=729754
|
[44]
|
WHO (2008) Update on avian influenza A (H5N1) virus infection in humans. New England Journal of Medicine, 358, 261-273. doi.10.1056/NEJMra0707279
|
[45]
|
de Jong, M.D., et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. New England Journal of Medicine, 353, 2667-2672.
doi.10.1056/NEJMoa054512
|
[46]
|
De Marco, D., et al. (2012) A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLoS ONE, 7, e34415. doi:10.1371/journal.pone.0034415
|
[47]
|
Mozdzanowska, K., et al. (1997) A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. Journal of Virology, 71, 4347-4355.
http://jvi.asm.org/content/71/6/4347.abstract
|
[48]
|
Prabakaran, M., et al. (2009) Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS ONE, 4, e5672. doi:10.1371/journal.pone.0005672
|
[49]
|
Simmons, C.P., et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLOS Medicine, 4, e178.
doi:10.1371/journal.pmed.0040178
|
[50]
|
Király, J., et al. (2011) Evaluation of anti-influenza efficiency of polyclonal IgG antibodies specific to the ectodomain of M2 protein of influenza A virus by passive immunization of mice. Acta Virologica, 55, 261-265.
doi:10.4149/av_2011_03_261
|